Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

ClinicalTrials.gov ID: NCT06834074

Public ClinicalTrials.gov record NCT06834074. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 19, 2026, 12:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Expanded Access Treatment of Neladalkib (NVL-655) in Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

Study identification

NCT ID: NCT06834074
Recruitment status: Available
Study type: Expanded access
Phase: Not listed
Lead sponsor: Nuvalent Inc.; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Interventions

NVL-655 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Not listed
Primary completion: Not listed
Completion: Not listed
Last update posted: May 13, 2026

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 11

Facility	City	State	ZIP	Site status
University Of California Irvine Medical Center	Orange	California	92868	Available
University of Colorado Anschutz School of Medicine	Aurora	Colorado	80045	Available
University of Chicago Medical Center	Chicago	Illinois	60637	Available
Massachusetts General Hospital	Boston	Massachusetts	02114	Available
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Available
Henry Ford Cancer Institute	Detroit	Michigan	48202	Available
Washington University in St. Louis	St Louis	Missouri	63110	Available
NYU Langone Health	New York	New York	10016	Available
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Available
Duke University	Durham	North Carolina	27708	Available
The Ohio State University	Columbus	Ohio	43210	Available
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Available
University of Washington / Fred Hutchinson Cancer Center	Seattle	Washington	98109	Available

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06834074, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 13, 2026 · Synced May 19, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06834074 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →